ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1233
0,00%
Bitcoin
69.770,34
-0,51%
Brent Oil
82,25
-0,24%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ambrx Biopharma Inc (AMAM)

  7. Ambrx Biopharma Inc (AMAM) Notícias

AMAM

Ambrx Biopharma (AMAM)

Ambrx Biopharma Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AMAM
DataHoraFonteTítuloCódigoCompanhia
18/03/202415:45Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:AMAMAmbrx Biopharma Inc
12/03/202417:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMAMAmbrx Biopharma Inc
11/03/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AMAMAmbrx Biopharma Inc
08/03/202415:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:AMAMAmbrx Biopharma Inc
07/03/202415:23Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AMAMAmbrx Biopharma Inc
23/02/202416:09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AMAMAmbrx Biopharma Inc
12/02/202415:43PR Newswire (US)Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law FirmNASDAQ:AMAMAmbrx Biopharma Inc
10/01/202417:07PR Newswire (US)Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law FirmNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202416:54Dow Jones NewsTrending: Johnson & Johnson and Merck & Co. Announce AcquisitionsNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202412:04Dow Jones NewsAmbrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & JohnsonNASDAQ:AMAMAmbrx Biopharma Inc
08/01/202410:12Dow Jones NewsJohnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 BillionNASDAQ:AMAMAmbrx Biopharma Inc
15/09/202317:27Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:AMAMAmbrx Biopharma Inc
19/07/202310:49Dow Jones NewsAmbrx Biopharma Gets Fast Track Designation for ARX517 Cancer TreatmentNASDAQ:AMAMAmbrx Biopharma Inc
28/06/202317:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202317:45Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AMAMAmbrx Biopharma Inc
28/06/202317:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AMAMAmbrx Biopharma Inc
25/05/202317:08Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AMAMAmbrx Biopharma Inc
18/05/202317:28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AMAMAmbrx Biopharma Inc
16/05/202317:07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AMAMAmbrx Biopharma Inc
11/05/202317:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AMAMAmbrx Biopharma Inc
05/05/202317:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:AMAMAmbrx Biopharma Inc
28/04/202317:22Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:AMAMAmbrx Biopharma Inc
28/04/202317:09Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AMAMAmbrx Biopharma Inc
27/04/202317:11Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AMAMAmbrx Biopharma Inc
18/04/202317:16Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:AMAMAmbrx Biopharma Inc
03/04/202307:18Edgar (US Regulatory)Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)NASDAQ:AMAMAmbrx Biopharma Inc
30/03/202318:23Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:AMAMAmbrx Biopharma Inc
30/03/202317:10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AMAMAmbrx Biopharma Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AMAM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
KRSA3
Kora Saude Participacoes... ON
BOV
BEEF3
MINERVA ON
BOV
IRBR3
IRB BRASIL ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados